FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Sollie-Zetlmayer Hege Elisabeth
(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE
(Street)
WARREN NJ 07059
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/28/2026 		3. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 46,526 (1)
D
 
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 10/22/2030 Common Stock 14,000 51.96 D  
Stock Option (Right to Buy)   (2) 01/05/2031 Common Stock 33,250 66.49 D  
Stock Option (Right to Buy)   (2) 01/06/2032 Common Stock 17,875 38.1 D  
Stock Option (Right to Buy)   (3) 01/04/2033 Common Stock 11,250 39.42 D  
Stock Option (Right to Buy)   (4) 02/14/2034 Common Stock 25,000 25.69 D  
Stock Option (Right to Buy)   (5) 01/02/2035 Common Stock 25,000 46.54 D  
Stock Option (Right to Buy)   (6) 01/01/2036 Common Stock 27,500 76.74 D  
Explanation of Responses:
1. Includes (1) 2,250 unvested Restricted Stock Units ("RSUs") from an award of 9,000 RSUs granted on January 5, 2023, which vests in four equal installments over four years, commencing on January 5, 2024; (2) 5,000 unvested RSUs from an award of 10,000 RSUs granted on February 15, 2024, which vests in four equal installments over four years, commencing on February 15, 2025; (3) 7,500 unvested RSUs from an award of 10,000 RSUs granted on January 3, 2025, which vests in four equal installments over four years, commencing on January 3, 2026; and (4) 11,000 unvested RSUs from an award of 11,000 RSUs granted on January 2, 2026, which vests in four equal installments over four years, commencing on January 2, 2027.
2. Currently exercisable.
3. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
4. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
5. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
6. This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
/s/ Avraham S. Adler, Attorney-in-Fact 07/30/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

ex24-07312026_010712.htm